GlycoMimetics registers $86m IPO for orphan disease programs
This article was originally published in Scrip
Executive Summary
Now that Pfizer has taken on Phase III development for GlycoMimetics's lead drug candidate GMI-1070 for sickle cell disease, and since it had just $10.8m in cash as of 30 June, the Gaithersburg, Maryland-based company has registered for an initial public offering to raise up to $86.25m for early clinical and preclinical programs.